A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

NCT07227025 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Amivantamab
DRUG: Olomorasib

Sponsor

Janssen Research & Development, LLC